InflaRx (IFRX) Common Equity (2016 - 2026)

InflaRx has disclosed Common Equity across 11 years of filings, most recently posting $169.9 million for Q2 2026.

• In Q2 2026, Common Equity rose 163.15% year-over-year to $169.9 million; the TTM figure through Jun 2026 stood at $169.9 million (up 163.15% YoY), while the FY2025 annual figure was $47.0 million, down 28.46% from the prior year.
• Common Equity came in at $169.9 million for Q2 2026 at InflaRx, up from $43.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $169.9 million in Q2 2026 to a low of $43.2 million in Q1 2026.
• Average Common Equity over 5 years is $91.5 million, with a median of $89.3 million recorded in 2022.
• Year-over-year, Common Equity plunged 44.18% in 2024 and soared 163.15% in 2026.
• Over 5 years, Common Equity stood at $90.1 million in 2022, then increased by 22.45% to $110.4 million in 2023, then tumbled by 40.54% to $65.6 million in 2024, then dropped by 26.29% to $48.4 million in 2025, then jumped by 251.26% to $169.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $169.9 million in Q2 2026, $43.2 million in Q1 2026, and $48.4 million in Q4 2025.